Lantheus files Schedule 13D showing 20.9% stake in Radiopharm Theranostics
Lantheus Holdings disclosed a 20.9% beneficial stake in Radiopharm Theranostics Limited in a Schedule 13D filed September 4, 2026, with shares and options accumulated across 2024 and 2025.
Lantheus Holdings, Inc. disclosed a 20.9% beneficial stake in Radiopharm Theranostics Limited in a Schedule 13D filed on September 4, 2026. The filing says the position was built through shares and options accumulated across 2024 and 2025 as part of a broader deal involving asset transfers and… The disclosure also references 4 related elements in the transaction structure.